Spero Therapeutics Inc SPRO

$SPRO This stock is owned by short sellers.

$SPRO no doubt UK based global GSK wants UK & EU EMA appr of tebi too and under brilliant Tony Wood CSO is already well on their way to get this done asap in '27. GSK will save countless lives, needless hosp visits, make billions of sales globally with it, and imo believe they'll re-negot w spro to own it all, and spro sh value boldly takes off. long and

$SPRO this shit was at 2.20 not long ago 😂

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: $LABT ) said in an October 1, 2026 release that Chief Executive Officer Kelvin Cooper, Ph.D., will participate in three industry conferences this month. The clinical-stage company is developing the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials for infectious diseases, and its lead candidate Nu-3 is a topical gel for infected diabetic foot ulcers. Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 Dr. Cooper's schedule moves from two New York City conferences, one featuring a company presentation, to presenting a poster on Nu-3 preclinical data at IDWeek in Washington, D.C.: • Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, during the October 13-14 event at the Hard Rock Hotel in New York City • At the ThinkEquity Conference on October 15 at The Mandarin Oriental Hotel in New York City, he will attend and give a 3:30 pm presentation on Nu-3 and its in vitro activity against resistant pathogens, for the treatment of infected diabetic foot ulcers • IDWeek runs October 21-24 at the Walter E. Washington Convention Center in Washington, D.C., with a hybrid format available, and he will present a poster on Nu-3 preclinical data there on October 22 Across all three conferences, the company has opportunities to engage with members of the investment, biotechnology and infectious disease communities and to highlight its ongoing development programs in Bisphosphocin® antimicrobial technology. Read the full release: https://lakewoodamedex.investorroom.com/2026-10-01-Lakewood-Amedex-Biotherapeutics-Announces-Participation-in-October-Conferences Lakewood-Amedex Biotherapeutics, Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $SPRO, $CDTX, $SCYX, $XBI

Anti-infectives: can $CRMD, $INVA, $SPRO and $SCYX turn approvals into durable cash flow? https://www.merlintrader.com/anti-infectives/

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: $LABT ) Chief Executive Officer Kelvin Cooper, Ph.D., sat down with Proactive after the company dosed the first patient in its Phase 2a trial of Nu-3, a topical antimicrobial gel for mildly infected diabetic foot ulcers, and explained why that indication came first. Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 Cooper described an approach that runs against the usual course of oral antibiotics, in his words "a different approach than many antibiotic approaches, which typically go through an oral, a tablet that you take for a whole course of treatment": • The company's compounds target antimicrobial-resistant bacteria, and, as Cooper put it, "we treat a disease where it occurs, the infection where it occurs": skin on the skin, lung in the lung, bladder in the bladder • Infected diabetic foot ulcers came first because a regulatory filing requires a single indication, and, in Cooper's words, "it's a very serious disease, not well treated" • The Phase 2a study is multicenter, single-blinded and dose-finding, evaluating Nu-3 gel at 2%, 5% and 10%, with topline data expected in the first quarter of 2027 On the trial's purpose, Cooper said: "And what we are aiming to do with our clinical trial is to go into a patient that's just discovered they've got an infection and sort of cap it right there. So we've got a topical drug. You apply it directly to the wound. It's a gel, and it will kill the bacteria in the wound." Watch the full segment: https://www.proactiveinvestors.com/companies/news/1099239/lakewood-amedex-doses-first-patient-in-phase-2a-trial-for-diabetic-foot-infections.html On what the trial is meant to establish, Cooper noted, "We call this trial a proof of concept trial. In clinical terminology, you don't know you've got something until you prove it in human beings, and that's our proof." He was explicit that any broader use depends on the result: "If it works, then yes, if we can apply the drug into the lung, we should be able to treat lung infections. Into the bladder, we should be able to treat bladder infections." Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $SPRO, $CDTX, $SCYX, $XBI

$LABT $SCYX $XBI $SPRO

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: $LABT ) reported positive Minimum Inhibitory Concentration (MIC) data from in vitro testing of its lead clinical candidate, Nu-3, against recent clinical isolates from infected diabetic foot ulcers. Nu-3, a topically formulated Bisphosphocin®, is currently being investigated in a Phase 2a clinical trial in mildly infected diabetic foot ulcers (iDFU), with topline data expected in the first quarter of 2027. Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 In this in vitro study, Nu-3 showed consistent activity against all organisms tested, including the drug-resistant strains: • The isolates were collected within the last 3 years from patients with diabetic foot infections at 14 U.S. medical centers • Pathogens tested included resistant and susceptible Staphylococcus aureus (MRSA and MSSA) and resistant and susceptible Enterococcus faecalis (VRE and VSE) • Antibacterial activity of Nu-3 was not affected by the drug resistance phenotype • MIC values were 2 to 8 times lower than the doses planned for clinical trials Regarding the isolates, Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, said: "Importantly, the data show clear and positive cidal activity against specific microbes isolated from real world patients. These microbes are a clear threat to patients with iDFU, and more broadly represent the global threat of antibiotic resistance." Read the full release: https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-data-against-recent-clinical-isolates-from-infected-diabetic-foot-ulcers-302890943.html Of the 830 million people in the world with diabetes, about one third will develop a diabetic foot ulcer, close to 50% of those ulcers become infected, and 15% to 20% of infected ulcers involve resistant pathogens, primarily MRSA. Results in the new testing fell within the range of earlier assays covering 285 clinical isolates across 15 species, and S. aureus (ATCC 29213) and E. faecalis (ATCC 29212) served as control strains. Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 In this in vitro study, Nu-3 showed consistent activity against all organisms tested, including the drug-resistant strains: • The isolates were collected within the last 3 years from patients with diabetic foot infections at 14 U.S. medical centers • Pathogens tested included resistant and susceptible Staphylococcus aureus (MRSA and MSSA) and resistant and susceptible Enterococcus faecalis (VRE and VSE) • Antibacterial activity of Nu-3 was not affected by the drug resistance phenotype • MIC values were 2 to 8 times lower than the doses planned for clinical trials Regarding the isolates, Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, said: "Importantly, the data show clear and positive cidal activity against specific microbes isolated from real world patients. These microbes are a clear threat to patients with iDFU, and more broadly represent the global threat of antibiotic resistance." Read the full release: https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-data-against-recent-clinical-isolates-from-infected-diabetic-foot-ulcers-302890943.html Of the 830 million people in the world with diabetes, about one third will develop a diabetic foot ulcer, close to 50% of those ulcers become infected, and 15% to 20% of infected ulcers involve resistant pathogens, primarily MRSA. Results in the new testing fell within the range of earlier assays covering 285 clinical isolates across 15 species, and S. aureus (ATCC 29213) and E. faecalis (ATCC 29212) served as control strains. Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $SCYX, $XBI $SPRO